Nutriband Inc.
NTRB
Positions held
Your positionsNTRB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $73.54M | Enterprise value | $70.34M | Trailing P/E | — | Forward P/E | -26.30 |
| PEG | — | Price / book | 13.81 | Beta | 1.93 | Dividend yield | 0.00% |
| Revenue growth | -29.7% | Earnings growth | — | Gross margin | 33.1% | Operating margin | -2.0% |
| Profit margin | 0.0% | ROE | -100.7% | ROA | -53.5% | Debt / equity | 0.04 |
| Current ratio | 4.21 | Free cash flow | -$1.41M | Analyst recommendation | none | Mean target | $15.00 |
| 52w high | $9.19 | 52w low | $2.80 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | $0.4M | $0.4M | $0.3M | $0.6M | — |
| Op margin | -203.6% | -289.4% | -254.8% | -1121.3% | -321.8% | — |
| Net income | -$0.9M | -$1.2M | -$1.0M | -$3.9M | -$2.0M | — |
| Gross margin | 41.6% | 45.4% | 22.2% | 19.8% | 25.2% | — |
| Gross profit | $0.2M | $0.2M | $0.1M | $0.1M | $0.2M | — |
| Operating income | -$0.9M | -$1.3M | -$1.0M | -$3.9M | -$2.0M | — |
- Revenue +1% vs prior quarter ($0.4M vs $0.4M).
- Gross margin 41.6% (was 45.4% prior quarter).
- Operating margin expanded to -203.6%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $2.0M | $2.1M | $2.1M | $2.1M | — |
| Op margin | -408.4% | -312.7% | -233.6% | -199.5% | — |
| Net income | -$8.2M | -$10.5M | -$5.5M | -$4.5M | — |
| Gross margin | 27.8% | 34.7% | 41.3% | 36.1% | — |
| Gross profit | $0.6M | $0.7M | $0.9M | $0.8M | — |
| Operating income | -$8.3M | -$6.7M | -$4.9M | -$4.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
2026-09-29 · Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
2026-09-25 · Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
2026-09-22 · Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
2026-09-09 · Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
2026-08-13 · Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Price (daily)
Full chart · RSI · MACD · patterns